Validation of the "Metroticket" model in a cohort of patients transplanted for hepatocellular carcinoma in southern Brazil

Clinical Transplantation

Volumn 29, Issue 9, 2015, Pages 806-812

  Machado, Adriana ^a   Kiss, Guillermo ^b   Ernani, Lucas ^a   Marroni, Claudio ^a,b   Zanotelli, Maria Lúcia ^b   Cantisani, Guido ^b   Cerski, Carlos Thadeu ^b   Coral, Gabriela ^a   Brandão, Ajacio ^a,b   de Medeiros Fleck, Alfeu ^c   Schlindwein, Eduardo ^c   Leipnitz, Ian ^c   Martini, Juliano ^c   Mucenic, Marcos ^c   Meine, Mário Henrique ^c  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^b Liver Transplantation Group   (Brazil)

^c NONE

Author keywords

Hepatocellular carcinoma; Liver cancer; Liver transplantations; Patient outcome assessments; Survival analysis

Indexed keywords

ADULT; ARTICLE; BRAZIL; CANCER PATIENT; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METROTICKET MODEL; MODEL; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VALIDATION STUDY; AGED; CARCINOMA, HEPATOCELLULAR; DECISION SUPPORT SYSTEM; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME;

ADULT; AGED; BRAZIL; CARCINOMA, HEPATOCELLULAR; DECISION SUPPORT TECHNIQUES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; ROC CURVE; TREATMENT OUTCOME;

EID: 84940960848     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12583     Document Type: Article

References (15)

1. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011: 53: 1020.
2. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996: 334: 693.
3. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009: 10: 35.
4. Raj A, McCall J, Gane E. Validation of the "Metroticket" predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carcinoma. J Hepatol 2011: 55: 1063.
5. Lei JY, Wang WT, Yan LN. "Metroticket" predictor for assessing liver transplantation to treat hepatocellular carcinoma: a single-center analysis in mainland China. World J Gastroenterol 2013: 19: 8093.
6. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973: 60: 646.
7. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001: 33: 464.
8. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001: 35: 421.
9. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005: 42: 1208.
10. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic curve (ROC) curve. Radiology 1982: 143: 29.
11. Carrilho FJ, Kikuchi L, Branco F, Goncalves CS, Mattos AA. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. Clinics (Sao Paulo) 2010: 65: 1285.
12. Zou KH, O'Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation 2007: 115: 654.
13. Bittermann T, Hoteit MA, Abt PL, Forde KA, Goldberg D. Waiting time and explant pathology in transplant recipients with hepatocellular carcinoma: a novel study using national data. Am J Transplant 2014: 14: 1657.
14. Fan L, Mac MT, Frishberg DP et al. Interobserver and intraobserver variability in evaluating vascular invasion in hepatocellular carcinoma. J Gastroenterol Hepatol 2010: 25: 1556.
15. Montalti R, Mimmo A, Rompianesi G et al. Absence of viable HCC in the native liver is an independent protective factor of tumor recurrence after liver transplantation. Transplantation 2014: 97: 220.